Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 09, 2025 07:00 ET | Source: Secura Bio

Secura Bio Announces First Patient Dosed in Phase 3 TERZO Study of COPIKTRA® (duvelisib) in Relapsed/Refractory Nodal T-follicular Helper Cell Lymphoma

SUMMERLIN, Nev., June 09, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced...
December 09, 2024 07:00 ET | Source: Secura Bio

New Combination Data of Secura Bio’s COPIKTRA® (duvelisib) Presented at the 2024 American Society of Hematology Meeting

Dr. Alison Moskowitz presented results of a Phase 1 study of combination duvelisib plus ruxolitinib in relapsed/refractory (R/R) peripheral T-cell lymphoma or cutaneous T-cell lymphoma Results...
December 09, 2024 07:00 ET | Source: Secura Bio

Secura Bio Presented New Data from its Phase 2 PRIMO Trial of Copiktra® (Duvelisib) in Relapsed or Refractory Peripheral T-cell Lymphoma and Announced Plans for its Phase 3 TERZO Trial at the 2024 American Society of Hematology Meeting

Data from the Phase 2 PRIMO trial in 123 patients showed an overall response rate (ORR) of 48%, a complete response (CR) rate of 33%, and a median duration of response (DOR) of 7.89 months The...
November 14, 2024 16:00 ET | Source: Secura Bio

Secura Bio Appoints Dr. Patrick Vink as Chairman of the Board of Directors

SUMMERLIN, Nev., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company dedicated to the worldwide development and commercialization of...
November 06, 2024 07:00 ET | Source: Secura Bio

Secura Bio Announces Poster Presentation Highlighting New COPIKTRA® (duvelisib) Data for the Treatment of Patients With Peripheral T-Cell Lymphoma and Other Advanced Hematologic Malignancies at the 2024 American Society of Hematology Meeting

SUMMERLIN, Nev., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company dedicated to the worldwide development and commercialization of...